Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD22 | P20273 | 6/20 | 0.51 |
| ▸ | MAG | P20916 | 4/20 | 0.51 |
| ▸ | NANP | Q8TBE9 | 1/20 | 0.43 |
| ▸ | SIGLEC7 | Q9Y286 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31695090 | 0.93 | CD22 (0.49) | CD22MAGNANP | |
| SCHEMBL31695218 | 0.88 | CD22 (0.46) | CD22MAGNANP | |
| SCHEMBL31502399 | 0.86 | CD22 (0.61) | CD22MAG | |
| SCHEMBL31695040 | 0.85 | CD22 (0.49) | CD22MAG | |
| SCHEMBL26927575 | 0.82 | CD22 (0.51) | CD22MAGNANP | |
| SCHEMBL23239793 | 0.76 | L3MBTL1 (0.39) | MAGNANPSIGLEC7 | |
| SCHEMBL31695064 | 0.75 | NANP (0.38) | CD22MAGNANPSIGLEC7 | |
| SCHEMBL8664356 | 0.74 | MAG (0.56) | CD22MAGNANPSIGLEC7 | |
| SCHEMBL31502370 | 0.74 | CD22 (0.73) | CD22MAG | |
| SCHEMBL31695272 | 0.74 | NANP (0.39) | MAGNANPSIGLEC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250313574-A1 | SIALIC ACID DERIVATIVES AND METHODS OF USING SAME | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2025-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250313574-A1 | SIALIC ACID DERIVATIVES AND METHODS OF USING SAME | NEU1, NEU2, NEU4 | CD22 295/4885MAG 136/4885NANP 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.